Ascent Industries (ACNT) Q4 2025 earnings summary

Executive summary

• Transitioned to a pure-play specialty chemical company, exiting legacy tubular segment and Munhall facility, resulting in a structurally stronger business with higher earnings power.

• Achieved significant operational improvements, including gross margin expansion and cost reductions, despite a challenging demand environment.

• Fourth quarter net sales rose 3.9% year-over-year to $18.8M, but gross profit declined 2.9% to $3.4M due to higher material and fulfillment costs.

• Net loss from continuing operations narrowed to ($5.6M) for 2025, a 54.6% improvement year-over-year.

• Two major divestitures (BRISMET and ASTI) were completed, with results from these businesses now classified as discontinued operations.

Financial highlights

• Gross margin expanded nearly 1,000 basis points year-over-year; gross profit increased 61%.

• Adjusted EBITDA improved by over $4 million year-over-year, despite a 7% decline in revenue.

• Full year 2025 net sales fell 7.3% to $74.9M, but gross profit surged 61% to $17.2M, with gross margin expanding by 9.7 percentage points to 23%.

• Q4 adjusted EBITDA loss widened to ($1.1M), with margin at (6.1)%, down from (3.1)% in Q4 2024.

• Repurchased 745,524 shares in 2025 for $9.2M at an average price of $12.26 per share.

Outlook and guidance

• Targeting double-digit revenue growth for 2026, driven by new commercial wins and a robust pipeline.

• Aims for consolidated gross margins in the high 20s% to low 30s% range for 2026, with long-term targets of 30%-35% gross margin and 15% EBITDA margin.

• Entering 2026 with a focused specialty chemicals platform, management expects higher-quality earnings and increased operating leverage to drive profitable growth as market conditions improve.